Female Reproductive System Adenocarcinoma

Female Reproductive System Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

454 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 158
Recruiting: 74
Ph III recruiting: 10
Growth YoY: +19%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (59)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04913337	Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies	unknown	Phase 1 / Phase 2	179	NGM Biopharmaceuticals, IncINDUSTRY	3	Oct 2, 2024	clinicaltrials
NCT05311618	Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors	unknown	Phase 1	71	NGM Biopharmaceuticals, IncINDUSTRY	1	Apr 1, 2024	clinicaltrials